Publications
Detailed Information
Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Seon-Hui | - |
dc.contributor.author | Lee, Choon-Taek | - |
dc.contributor.author | Hah, J. Hun | - |
dc.contributor.author | Lee, Jae-Jung | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Sung, Myung-Whun | - |
dc.contributor.author | Park, Seok-Woo | - |
dc.date.accessioned | 2012-07-04T08:50:37Z | - |
dc.date.available | 2012-07-04T08:50:37Z | - |
dc.date.issued | 2010-02 | - |
dc.identifier.citation | CANCER SCIENCE; Vol.101 2; 482-487 | ko_KR |
dc.identifier.issn | 1347-9032 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78491 | - |
dc.description.abstract | To overcome the low efficiency of gene therapy, we combined a conditionally replicating adenovirus (CRAd) and an adenoviral vector with a therapeutic gene. CRAd has an oncolytic activity in cancer cells with abnormal Rb activity and helps the replication of therapeutic genes incorporated in the E1-deleted adenovirus. We investigated the anticancer effect of a combination of CRAd and adenovirus carrying tumor necrosis factor-related apoptosis inducing ligand (ad-TRAIL). We expected to see increased gene expression in cancer cells as well as an antitumor effect. With the combined application of CRAd and ad-luciferase in head and neck cancer cell lines, we observed considerably increased luciferase activity that was 10- to 50-fold greater than with ad-luciferase alone. The combination of CRAd and ad-TRAIL showed significant suppression of growth in cell lines and increased the sub-G1 portion of cells 30-fold compared to any single treatment. The expression of TRAIL was highly amplified by the combined treatment and was accompanied by expression of molecules related to apoptosis. In a xenograft animal model, mice treated with CRAd and ad-TRAIL showed complete regression of established tumors, whereas mice treated with CRAd or ad-TRAIL alone did not. In conclusion, this combined strategy using CRAd and adenovirus carrying a therapeutic gene increased the gene transfer rate and enhanced antitumor effects. We expect that this combination strategy could be extended to a multitarget cancer gene therapy by combining multiple adenoviruses and CRAd. (Cancer Sci 2010; 101: 482-487) | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL PUBLISHING, INC | ko_KR |
dc.title | Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 심선휘 | - |
dc.contributor.AlternativeAuthor | 이춘택 | - |
dc.contributor.AlternativeAuthor | 이재정 | - |
dc.contributor.AlternativeAuthor | 박석우 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.contributor.AlternativeAuthor | 성명훈 | - |
dc.identifier.doi | 10.1111/j.1349-7006.2009.01409.x | - |
dc.citation.journaltitle | CANCER SCIENCE | - |
dc.description.citedreference | Ren XW, 2006, CANCER GENE THER, V13, P159, DOI 10.1038/sj.cgt.7700868 | - |
dc.description.citedreference | Lee CT, 2006, CANCER RES, V66, P372, DOI 10.1158/0008-5272.CAN-05-1515 | - |
dc.description.citedreference | Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792 | - |
dc.description.citedreference | Lee CT, 2004, CANCER RES, V64, P6660 | - |
dc.description.citedreference | Geoerger B, 2004, CANCER RES, V64, P5753 | - |
dc.description.citedreference | Davydova J, 2004, CANCER RES, V64, P4319 | - |
dc.description.citedreference | Kanerva A, 2004, GENE THER, V11, P552, DOI 10.1038/sj.gt.3302181 | - |
dc.description.citedreference | Huang Q, 2004, CLIN CANCER RES, V10, P1439 | - |
dc.description.citedreference | Jang SH, 2004, INT J MOL MED, V13, P181 | - |
dc.description.citedreference | Huang TG, 2003, GENE THER, V10, P1241, DOI 10.1038/sj.gt.3301987 | - |
dc.description.citedreference | Seol JY, 2003, CANCER GENE THER, V10, P540, DOI 10.1038/sj.cgt.7700597 | - |
dc.description.citedreference | Hermiston TW, 2002, CANCER GENE THER, V9, P1022, DOI 10.1038/sj.cgt.7700542 | - |
dc.description.citedreference | Nanda D, 2001, CANCER RES, V61, P8743 | - |
dc.description.citedreference | Hawkins LK, 2001, GENE THER, V8, P1123 | - |
dc.description.citedreference | Hawkins LK, 2001, GENE THER, V8, P1142 | - |
dc.description.citedreference | Hawkins LK, 2001, GENE THER, V8, P1132 | - |
dc.description.citedreference | Suzuki K, 2001, CLIN CANCER RES, V7, P120 | - |
dc.description.citedreference | Kirn D, 2000, ONCOGENE, V19, P6660 | - |
dc.description.citedreference | Eggert A, 2000, MED PEDIATR ONCOL, V35, P603 | - |
dc.description.citedreference | Heise C, 2000, NAT MED, V6, P1134 | - |
dc.description.citedreference | Ozoren N, 2000, INT J ONCOL, V16, P917 | - |
dc.description.citedreference | Kim KH, 2000, CLIN CANCER RES, V6, P335 | - |
dc.description.citedreference | Leverkus M, 2000, CANCER RES, V60, P553 | - |
dc.description.citedreference | Lee SH, 1999, CANCER RES, V59, P5683 | - |
dc.description.citedreference | Wildner O, 1999, CANCER RES, V59, P410 | - |
dc.description.citedreference | Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559 | - |
dc.description.citedreference | Griffith TS, 1998, J IMMUNOL, V161, P2833 | - |
dc.description.citedreference | Heise C, 1997, NAT MED, V3, P639 | - |
dc.description.citedreference | Wiley SR, 1995, IMMUNITY, V3, P673 | - |
dc.description.tc | 3 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.